[go: up one dir, main page]

MX2019014771A - Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña. - Google Patents

Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña.

Info

Publication number
MX2019014771A
MX2019014771A MX2019014771A MX2019014771A MX2019014771A MX 2019014771 A MX2019014771 A MX 2019014771A MX 2019014771 A MX2019014771 A MX 2019014771A MX 2019014771 A MX2019014771 A MX 2019014771A MX 2019014771 A MX2019014771 A MX 2019014771A
Authority
MX
Mexico
Prior art keywords
migraine
inhibitors
prevention
treatment
headache
Prior art date
Application number
MX2019014771A
Other languages
English (en)
Inventor
William Pullman
Original Assignee
Proximagen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Llc filed Critical Proximagen Llc
Publication of MX2019014771A publication Critical patent/MX2019014771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los inhibidores de la actividad de VAP-1/SSAO, y las composiciones farmacéuticas que los comprenden, son útiles para la prevención y/o el tratamiento de la migraña, incluyendo, dolor de cabeza, migraña crónica, migraña episódica, trastorno por dolor de cabeza debido al uso excesivo de medicamentos (MOU); migraña sin aura; migraña con aura; aura de migraña sin dolor de cabeza; migraña ocular; migraña vestibular; migraña basilar; migraña hemipléjica; migraña oftalmopléjica; y dolor de cabeza tensional (TTH).
MX2019014771A 2017-06-08 2018-06-08 Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña. MX2019014771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709136.4A GB201709136D0 (en) 2017-06-08 2017-06-08 New therapeutic uses of enzyme inhibitors
PCT/GB2018/051558 WO2018224837A1 (en) 2017-06-08 2018-06-08 Inhibitors of vascular adhesion protein-1 for use in prevention or treatment of migraine

Publications (1)

Publication Number Publication Date
MX2019014771A true MX2019014771A (es) 2020-08-03

Family

ID=59358222

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014771A MX2019014771A (es) 2017-06-08 2018-06-08 Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña.

Country Status (14)

Country Link
US (1) US20200147059A1 (es)
EP (1) EP3634393A1 (es)
JP (1) JP2020522537A (es)
KR (1) KR20200013767A (es)
CN (1) CN111032029A (es)
AU (1) AU2018281010A1 (es)
BR (1) BR112019025649A2 (es)
CA (1) CA3066037A1 (es)
EA (1) EA201992655A1 (es)
GB (1) GB201709136D0 (es)
IL (1) IL271288A (es)
MX (1) MX2019014771A (es)
SG (1) SG11201911648PA (es)
WO (1) WO2018224837A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201416444D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New compounds
CN112076184B (zh) * 2020-08-31 2021-08-03 山东省妇幼保健院 苄丝肼作为抗细菌剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3559572B2 (ja) * 1993-01-29 2004-09-02 住友製薬株式会社 急性痛および慢性痛用鎮痛剤
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
DE10220048A1 (de) * 2002-05-04 2003-11-13 Merck Patent Gmbh Semicarbazidderivate
CA2575928A1 (en) * 2004-08-02 2006-02-09 Genmedica Therapeutics Sl Compounds for inhibiting copper-containing amine oxidases and uses thereof
WO2006094201A2 (en) * 2005-03-02 2006-09-08 La Jolla Pharmaceutical Company Semicarbazide-sensitive amide oxidase inhibitors
US20070066646A1 (en) * 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP2134335B1 (en) * 2007-03-09 2014-04-23 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
TR201807453T4 (tr) * 2012-05-02 2018-06-21 Boehringer Ingelheim Int Ssao'nun sübstitüe 3-haloallilamin inhibitörleri ve bunların kullanımları.
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
ES2714125T3 (es) * 2014-04-15 2019-05-27 Pecsi Tudomanyegyetem Inhibidores de la amino oxidasa sensible a la semicarbazida para uso como analgésicos en una neuropatía traumática y una inflamación neurogénica
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
US20180360808A1 (en) * 2015-12-07 2018-12-20 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain

Also Published As

Publication number Publication date
SG11201911648PA (en) 2020-01-30
WO2018224837A1 (en) 2018-12-13
EP3634393A1 (en) 2020-04-15
CA3066037A1 (en) 2018-12-13
BR112019025649A2 (pt) 2020-11-03
US20200147059A1 (en) 2020-05-14
AU2018281010A1 (en) 2020-01-02
KR20200013767A (ko) 2020-02-07
GB201709136D0 (en) 2017-07-26
JP2020522537A (ja) 2020-07-30
IL271288A (en) 2020-01-30
EA201992655A1 (ru) 2020-06-03
CN111032029A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
GB201714430D0 (en) Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2019014771A (es) Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
HK1256174A1 (zh) 用於治疗疼痛的 vap-1 抑制剂
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
TW201613926A (en) Inhibitors of bruton&#39;s tyrosine kinase
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy